AMG-9810 is a drug which acts as a potent and selective antagonist for the TRPV1 receptor.[1] It has analgesic and antiinflammatory effects and is used in scientific research, but has not been developed for medical use. It has high antagonist potency and good bioavailability and pharmacokinetics, and so has been used to study the role of TRPV1 in areas other than pain perception, such as its roles in the brain.[2][3][4][5][6]
^Doherty EM, Fotsch C, Bo Y, Chakrabarti PP, Chen N, Gavva N, et al. (January 2005). "Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides". Journal of Medicinal Chemistry. 48 (1): 71–90. doi:10.1021/jm049485i. PMID15634002.
^Shirazi M, Izadi M, Amin M, Rezvani ME, Roohbakhsh A, Shamsizadeh A (August 2014). "Involvement of central TRPV1 receptors in pentylenetetrazole and amygdala-induced kindling in male rats". Neurological Sciences. 35 (8): 1235–41. doi:10.1007/s10072-014-1689-5. PMID24577898. S2CID24122557.
^Amiresmaili S, Shamsizadeh A, Allahtavakoli M, Pourshanazari AA, Roohbakhsh A (February 2014). "The effect of intra-ventral hippocampus administration of TRPV1 agonist and antagonist on spatial learning and memory in male rats". Pharmacological Reports. 66 (1): 10–4. doi:10.1016/j.pharep.2013.06.002. PMID24905300. S2CID15631269.
^Walters ET (August 2014). "Neuroinflammatory contributions to pain after SCI: roles for central glial mechanisms and nociceptor-mediated host defense". Experimental Neurology. 258: 48–61. doi:10.1016/j.expneurol.2014.02.001. PMID25017887. S2CID39671969.
^Bannazadeh M, Fatehi F, Fatemi I, Roohbakhsh A, Allahtavakoli M, Nasiri M, et al. (May 2017). "The role of transient receptor potential vanilloid type 1 in unimodal and multimodal object recognition task in rats". Pharmacological Reports. 69 (3): 526–531. doi:10.1016/j.pharep.2017.01.025. PMID31994094. S2CID210949267.